Literature DB >> 28667073

Cancer Cell-Autonomous Parainflammation Mimics Immune Cell Infiltration.

Audrey Lasry1, Dvir Aran2, Atul J Butte2, Yinon Ben-Neriah3.   

Abstract

Parainflammation is a unique variant of inflammation, characterized by epithelial-autonomous activation of inflammatory response. Parainflammation has been shown to strongly promote mouse gut tumorigenesis upon p53 loss. In a recent study, we explored the prevalence of parainflammation in human cancer and determined its relationship to certain molecular and clinical parameters affecting treatment and prognosis. Parainflammation can be identified from a 40-gene signature and is found in both carcinoma cell lines and a variety of primary tumors, independently of tumor microenvironment. Here, we discuss the implications of our findings in analyses of tumor microenvironment, suggesting that as tumor cell gene expression may often mimic immune and inflammatory infiltration, caution should be applied when interpreting tumor expression data. We also address the connection between parainflammation and prevalence of p53 mutations in specific types of tumors, and cancer prevention by regular usage of NSAIDs. We suggest that parainflammation may serve as a novel biomarker for screening patients who may particularly benefit from NSAID treatment. Cancer Res; 77(14); 3740-4. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28667073      PMCID: PMC5518753          DOI: 10.1158/0008-5472.CAN-16-3383

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO).

Authors:  Valerie A McCormack; Rayjean J Hung; Darren R Brenner; Heike Bickeböller; Albert Rosenberger; Joshua E Muscat; Philip Lazarus; Anne Tjønneland; Søren Friis; David C Christiani; Eun-Mi Chun; Loic Le Marchand; Gad Rennert; Hedy S Rennert; Angeline S Andrew; Irene Orlow; Bernard Park; Paolo Boffetta; Eric J Duell
Journal:  Cancer Causes Control       Date:  2011-10-11       Impact factor: 2.506

Review 3.  Lost in translation: animal models and clinical trials in cancer treatment.

Authors:  Isabella Wy Mak; Nathan Evaniew; Michelle Ghert
Journal:  Am J Transl Res       Date:  2014-01-15       Impact factor: 4.060

4.  Effect of sulindac on small polyps in familial adenomatous polyposis.

Authors:  H S Debinski; J Trojan; K P Nugent; A D Spigelman; R K Phillips
Journal:  Lancet       Date:  1995-04-01       Impact factor: 79.321

5.  Sulindac suppresses tumorigenesis in the Min mouse.

Authors:  Y Beazer-Barclay; D B Levy; A R Moser; W F Dove; S R Hamilton; B Vogelstein; K W Kinzler
Journal:  Carcinogenesis       Date:  1996-08       Impact factor: 4.944

6.  Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Authors:  Kimmie Ng; Jeffrey A Meyerhardt; Andrew T Chan; Kaori Sato; Jennifer A Chan; Donna Niedzwiecki; Leonard B Saltz; Robert J Mayer; Al B Benson; Paul L Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Alan P Venook; Shuji Ogino; Edward L Giovannucci; Charles S Fuchs
Journal:  J Natl Cancer Inst       Date:  2014-11-27       Impact factor: 13.506

Review 7.  Immune checkpoints and their inhibition in cancer and infectious diseases.

Authors:  Lydia Dyck; Kingston H G Mills
Journal:  Eur J Immunol       Date:  2017-04-24       Impact factor: 5.532

8.  Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies.

Authors:  Toni K Choueiri; Youjin Je; Eunyoung Cho
Journal:  Int J Cancer       Date:  2013-09-23       Impact factor: 7.396

9.  A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism.

Authors:  Ariel Pribluda; Ela Elyada; Zoltan Wiener; Haya Hamza; Robert E Goldstein; Moshe Biton; Ido Burstain; Yael Morgenstern; Guy Brachya; Hana Billauer; Sharon Biton; Irit Snir-Alkalay; Domagoj Vucic; Katharina Schlereth; Marco Mernberger; Thorsten Stiewe; Moshe Oren; Kari Alitalo; Eli Pikarsky; Yinon Ben-Neriah
Journal:  Cancer Cell       Date:  2013-07-25       Impact factor: 31.743

10.  NEOPLASIA IN A CORAL?

Authors:  D F SQUIRES
Journal:  Science       Date:  1965-04-23       Impact factor: 47.728

View more
  3 in total

1.  The Severity of Neurological Dysfunction in Preschool Children, Secondary to Damage Generated During the Perinatal Period, is Associated With a Pro-Inflammatory Pattern of Serum Molecules.

Authors:  Miriam Madrid; Malinalli Brianza-Padilla; Juan C Echeverría; Rolando Rivera-González; Rafael Bojalil
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

2.  Prediction of Prognosis in Patients With Endometrial Carcinoma and Immune Microenvironment Estimation Based on Ferroptosis-Related Genes.

Authors:  Shouze Liu; Qianqian Zhang; Wenhua Liu; Xianghua Huang
Journal:  Front Mol Biosci       Date:  2022-07-15

3.  siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.

Authors:  Shane P Duggan; Catherine Garry; Fiona M Behan; Sinead Phipps; Hiromi Kudo; Murat Kirca; Abdul Zaheer; Sarah McGarrigle; John V Reynolds; Robert Goldin; Steve E Kalloger; David F Schaeffer; Aideen Long; Jessica Strid; Dermot Kelleher
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.